Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
|
|
|
- Bernadette Rice
- 5 years ago
- Views:
Transcription
1 Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF symptoms Tachycardia R000 Chest pain R072, R073, R074 Palpitations R002 s Ischaemic stroke I63, I66, I67, unspecified I64 Haemorrhagic stroke I60 I62, I69 Transient ischaemic attack G45 Systemic embolism I74.2 I74.9 Haemorrhages Intracranial bleeding S064 S066 Gastric/duodenal ulcer K25 K28 (subcodes 0 2 and 4 6 only) Any severe bleeding I850, I983, K625, K922 Ischaemic heart disease I20 I25 Heart failure I50, I110, I130, I132, I131, I139 Including dyspnoea R060 Cardiac dysrhythmia I47, I490 I493 Abnormal cardiac conduction I44, I45, I494, I495, Z450, Z950 Valvular disease I05 I091, I33 I39, Q22, Q23 Mitral stenosis I342, I050, I052, Q232 Hypertension I10 I15 Diabetes mellitus E10 E14 s Myocardial infarction I21, I252 Peripheral arterial disease I70 I73 Occlusions I65, I77 Obesity E65 E66 Abnormal renal function N17 N19 (+N28) codes for renal insufficiency, transplantation (Z940, T861) and dialysis (Z49, Z992), E102, I12, I13 Liver disease K70 K77, procedures for liver transplantation or resection Dyslipidaemia E78 Thyroid disease E00 E07 Anaemia D50 D64 Platelet or coagulation defect D65 D69 Lung disease J40 J70, J961 Including emphysema and J43, J44 chronic obstructive pulmonary disease Alcohol-related diagnoses E244, F10, G312, G621, G721, I426, K292, K70, K860, O354, P043, Q860, T51, Y90, Y91, Z502, Z714 Dementia F00 F03 Accidental falls W00 W19, R26 Cancer within preceding 5 years Entire C-series Inflammatory diseases M05 M14, M45, M46, K50 K52, K81, K85 Digestive conditions Entire K-series Rheumatology Entire M-series Ophthalmology Entire H-series Pulmonology Entire J-series 1
2 Supplementary Table S2 Interactions and multivariable analysis of risk factors for death Interaction Statistical test p Value Age cancer 834 < Age renal failure 311 < Sex anaemia 212 < Age alcohol-related diagnoses 122 < Age lung disease 22 < All deaths OR (95% CI) OR (95% CI) (including interactions) Age 75 years (vs <65 years) 2.57 (2.47 to 2.68) 3.84 ( ) Renal failure* 1.85 ( ) 1.84 ( ) Cancer 1.81 ( ) Cancer age <65 years 5.35 ( ) Cancer age years 2.88 ( ) Cancer age 75 years 1.54 ( ) Lung disease* 1.58 ( ) 1.57 ( ) Age years (vs <65 years) 1.37 ( ) 1.64 ( ) Neurological disease* 1.34 ( ) 1.33 ( ) Alcohol-related diagnoses 1.32 ( ) 1.30 ( ) Anaemia* 1.29 ( ) 1.28 ( ) Heart failure* 1.26 ( ) 1.26 ( ) Women (vs men) 1.04 ( ) 1.02 ( ) s* 1.03 ( ) 1.04 ( ) Thyroid disease* 0.90 ( ) 0.90 ( ) Hypertension* 0.81 ( ) 0.81 ( ) *Reference is absent disease or condition. CI, confidence interval; OR, odds ratio. 2
3 Supplementary Table S3 Characteristics of atrial fibrillation patients hospitalised for heart failure in France in 2012 (n=87 339) (n=8316) Age range, N (%) <65 years 7755 (9) 254 (3) years (15) 655 (8) 75 years (76) 7407 (89) Women, N (%) (51) 4300 (52) Alcohol-related diagnosis 5069 (6) 431 (5) Anaemia (27) 2887 (35) Cancer (14) 1496 (18) Diabetes mellitus (29) 2375 (29) Dyslipidaemia (31) 2256 (27) Hypertension (75) 6288 (76) Inflammatory disease 8733 (10) 1003 (12) Liver failure 4333 (5) 692 (8) Lung disease (26) 2688 (32) Neurological disease 7307 (8) 1073 (13) Renal failure (31) 3886 (47) Thyroid disease (15) 1363 (16) Ischaemic 5129 (6) 498 (6) Haemorrhagic 791 (1) 94 (1) Unspecified 1421 (2) 150 (2) Intracranial 394 (0) 50 (1) Gastrointestinal 1021 (1) 135 (2) Other 791 (1) 94 (1) Systemic embolism 2920 (3) 351 (4) Transient ischaemic attack 2449 (3) 277 (3) Myocardial infarction 9705 (11) 1110 (13) Peripheral artery disease (12) 1163 (14) Occlusions 4532 (5) 493 (6) Other ischaemic heart disease (30) 2849 (34) Symptoms of AF 7090 (8) 588 (7) Heart failure (45) 4916 (59) Cardiac dysrhythmia 7907 (9) 919 (11) Abnormal cardiac conduction (22) 2248 (27) Valvular disease/surgery (27) 2575 (31) Mitral stenosis 1511 (2) 166 (2) Fall, N (%) 8793 (10) 1218 (15) 3
4 Supplementary Table S4 Characteristics of atrial fibrillation patients hospitalised for ischaemic stroke in France in 2012 (n=17 295) (n=2614) Age group, N (%) <65 years 2648 (15) 212 (8) years 1394 (8) 66 (3) 75 years (77) 2336 (89) Women, N (%) 9780 (57) 1612 (62) Alcohol-related diagnosis 795 (5) 109 (4) Anaemia 2535 (15) 499 (19) Cancer 2035 (12) 361 (14) Diabetes mellitus 3788 (22) 601 (23) Dyslipidaemia 5162 (30) 577 (22) Hypertension (72) 1927 (74) Inflammatory disease 1310 (8) 202 (8) Liver failure 400 (2) 66 (3) Lung disease 2920 (17) 784 (30) Neurological disease 2139 (12) 412 (16) Renal failure 2561 (15) 570 (22) Thyroid disease 1976 (11) 338 (13) Ischaemic 2057 (12) 310 (12) Haemorrhagic 290 (2) 46 (2) Unspecified 467 (3) 76 (3) Intracranial 120 (1) 17 (1) Gastrointestinal 133 (1) 28 (1) Other 290 (2) 46 (2) Systemic embolism 451 (3) 101 (4) Transient ischaemic attack 849 (5) 104 (4) Myocardial infarction 987 (6) 195 (7) Peripheral artery disease 1178 (7) 270 (10) Occlusions 661 (4) 108 (4) Other ischaemic heart disease 2641 (15) 494 (19) Symptoms of AF 865 (5) 127 (5) Heart failure 3306 (19) 739 (28) Cardiac dysrhythmia 813 (5) 144 (6) Abnormal cardiac conduction 1986 (11) 374 (14) Valvular disease/surgery 1557 (9) 309 (12) Mitral stenosis 103 (1) 20 (1) Fall, N (%) 1669 (10) 364 (14) 4
5 Supplementary Table S5 Characteristics of atrial fibrillation patients hospitalised for intracranial haemorrhage in France in 2012 (n=1450) (n=335) Age group, N (%) <65 years 185 (13) 25 (7) years 86 (6) 7 (2) 75 years 1179 (81) 303 (90) Women, N (%) 603 (42) 138 (41) Alcohol-related diagnosis 120 (8) 24 (7) Anaemia 302 (21) 89 (27) Cancer 219 (15) 63 (19) Diabetes mellitus 325 (22) 84 (25) Dyslipidaemia 343 (24) 82 (24) Hypertension 1043 (72) 239 (71) Inflammatory disease 106 (7) 19 (6) Liver failure 57 (4) 16 (5) Lung disease 252 (17) 87 (26) Neurological disease 250 (17) 57 (17) Renal failure 283 (20) 87 (26) Thyroid disease 184 (13) 33 (10) Ischaemic 99 (7) 30 (9) Haemorrhagic 80 (6) 14 (4) Unspecified 29 (2) 10 (3) Intracranial 118 (8) 14 (4) Gastrointestinal 9 (1) 6 (2) Other 80 (6) 14 (4) Systemic embolism 38 (3) 8 (2) Transient ischaemic attack 54 (4) 11 (3) Myocardial infarction 94 (6) 28 (8) Peripheral artery disease 112 (8) 40 (12) Occlusions 59 (4) 16 (5) Other ischaemic heart disease 277 (19) 72 (21) Symptoms of AF 86 (6) 29 (9) Heart failure 388 (27) 119 (36) Cardiac dysrhythmia 100 (7) 30 (9) Abnormal cardiac conduction 243 (17) 64 (19) Valvular disease/surgery 174 (12) 60 (18) Mitral stenosis 9 (1) 3 (1) Fall, N (%) 204 (14) 57 (17) 5
Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
Supplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
Common Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
Definitions of chronic conditions used to define the number of serious comorbidities in the study.
Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
The contractor establishes and maintains a register of patients with AF
Atrial Fibrillation The contractor establishes and maintains a register of patients with AF G5731 Those patients with AF in whom there is a record of CHADS2 score of 1, the % of patients who are currently
Supplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
Supplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
SUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
Supplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
SUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records Riccardo Miotto 1,2, Li Li 1,2, Brian A. Kidd 1,2, and Joel T. Dudley
Process Measure: Screening for Adult Obstructive Sleep Apnea
Process Measure: Screening for Adult Obstructive Sleep Apnea Measure Description Description Type of Measure All patients aged 18 years and older at high risk for obstructive sleep apnea (OSA) with documentation
Supplementary Online Content
Supplementary Online Content Lau WCY, Chan EW, Cheung CL, et al. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA.
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG
Alison Tennant MRPharmS MPH Head of Service Improvement and Quality Dudley CCG Commissioning is the set of linked activities required to assess the healthcare needs of a population, specify the services
Cardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death
Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)
14/15 Threshold 15/16 Points 15/16. Points. Retired Replaced by NM82/AF007. Replacement NO CHANGE
SUMMARY OF CHANGES TO QOF 2015/1 - ENGLAND KEY No change Retired/replaced Wording and/or change Point or threshold change Indicator ID change 14/15 QOF ID 15/1 QOF ID NICE ID Indicator wording Changes
SUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
Atrial fibrillation patients do not benefit from acetylsalicylic acid
Europace (2014) 16, 631 638 doi:10.1093/europace/eut333 CLINICAL RESEARCH Atrial fibrillation Atrial fibrillation patients do not benefit from acetylsalicylic acid Sara Själander 1 *, Anders Själander
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
ARRHYTHMIAS AND DEVICE THERAPY
Topic List A BASICS 1 History of Cardiology 2 Clinical Skills 2.1 History Taking 2.2 Physical Examination 2.3 Electrocardiography 2.99 Clinical Skills - Other B IMAGING 3 Imaging 3.1 Echocardiography 3.2
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Appendix 1: Supplementary tables [posted as supplied by author]
![Appendix 1: Supplementary tables [posted as supplied by author]](/thumbs/81/83505567.jpg "Appendix 1: Supplementary tables [posted as supplied by author]")
Appendix 1: Supplementary tables [posted as supplied by author] Table A. International Classification of Diseases, Ninth Revision, Clinical Modification Codes Used to Define Heart Failure, Acute Myocardial
ACOFP 55th Annual Convention & Scientific Seminars. How Complicated is Your Panel? Effective Risk Coding in Primary Care. Alison Mancuso, DO, FACOFP
8 ACOFP 55th Annual Convention & Scientific Seminars How Complicated is Your Panel? Effective Risk Coding in Primary Care Alison Mancuso, DO, FACOFP How Complicated is Your Panel?: Effective Risk Coding
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE. Cranial Health History Form
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE Cranial Health History Form Welcome to the Neurosurgery Department at Washington University. To help us treat you, please fill this form out completely. Your Name:
Outline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
New indicators to be added to the NICE menu for the QOF and amendments to existing indicators
New indicators to be added to the for the QOF and amendments to existing indicators 1 st September 2015 Version 1.1 This document was originally published on 3 rd August 2015, it has since been updated.
University of Bristol - Explore Bristol Research
Rogers, C., Capoun, R., Scott, L., Taylor, J., Angelini, G., Narayan, P.,... Ascione, R. (2017). Shortening cardioplegic arrest time in patients undergoing combined coronary and valve surgery: results
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND CLINICAL
SUMMARY OF CHANGES TO QOF 2017/18 - ENGLAND KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 1/17 QOF ID 17/18 QOF ID NICE ID Indicator wording
A DAYS CARDIOVASCULAR UNIT GUIDE DUE WEDNESDAY 4/12
A DAYS CARDIOVASCULAR UNIT GUIDE DUE WEDNESDAY 4/12 MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY 3/20 - B 3/21 - A 3/22 - B 3/23 - A 3/24 - B 3/27 - A Dissection Ethics Debate 3/28 - B 3/29 - A Intro to Cardiovascular
Cardiology/Cardiothoracic
Cardiology/Cardiothoracic ICD-9-CM to ICD-10-CM Code Mapper 800-334-5724 www.contexomedia.com 2013 ICD-9-CM 272.0 Pure hypercholesterolemia 272.2 Mixed hyperlipidemia 272.4 Other and hyperlipidemia 278.00
ischemic stroke, transient ischemic attack, or peripheral artery embolism
Appendix Table S1: ICD- 8/1 codes and ATC- codes Population Acute myocardial infarction Defined from primary inpatient diagnoses codes PCI Defined from procedure codes Non- valvular atrial fibrillation
17/18 Threshold 18/19 Points 18/19. Points NO CHANGE NO CHANGE NO CHANGE
SUMMARY OF CHANGES TO QOF 2018/19 - ENGLAND 18-19 QOF005 KEY No change Retired/replaced Wording and/or timeframe change Point or threshold change Indicator ID change 17/18 QOF ID 18/19 QOF ID NICE ID Indicator
High Risk OSA n = 5,359
Table S1 Prevalence of atrial fibrillation (AF) identified using different methods in participants with high and low risk obstructive sleep apnea (). High Risk n = 5,359 Low Risk n = 14,992 SR-AF (%) 467
HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
AF Diagnosis. Incorporated into over 75 health checks and Public Health Checks
AF Diagnosis Incpated into over 75 health checks and Public Health Checks Pulse Feel the pulse in all >65yrs If irregular do a 12 Lead ECG with Rhythm strip Check Thyroid and FBC and heart rate Refer to
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
Supplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Apixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
Surgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
Downloaded from:
Antithrombotic Trialists Collaboration. (inc. Meade, TW), (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
Supplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
Acute stroke. Ischaemic stroke. Characteristics. Temporal classification. Clinical features. Interpretation of Emergency Head CT
Ischaemic stroke Characteristics Stroke is the third most common cause of death in the UK, and the leading cause of disability. 80% of strokes are ischaemic Large vessel occlusive atheromatous disease
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Ischemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012
SAMUEL TCHWENKO, MD, MPH Epidemiologist, Heart Disease & Stroke Prevention Branch Chronic Disease & Injury Section; Division of Public Health NC Department of Health & Human Services JUSTUS WARREN TASK
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Congestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
MDGuidelines API: Case Fit v3 Specification 1.3
MDGuidelines API: Case Fit v3 Specification 1.3 Date: August 23, 2017 1 Overview 1.1 Purpose and Intended Audience The purpose of this document is to provide detailed descriptions and specifications for
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
Listen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need
Listen to Your Heart The S-ICD System What Everyone Needs To Know About Atrial Fibrillation & Stroke The protection you need without Stroke. touching Are you your at heart risk? Increase your knowledge.
Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes Yes Unknown
Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes HbA1c If medication; - Insulin - Oral antidiabetic - Both - Diet - treatment : Fasting blood sugar 7 mmol/l or post glucose 11.1 mmol/l and/or
The Burden of Cardiovascular Disease in North Carolina. Justus-Warren Heart Disease and Stroke Prevention Task Force April 11, 2018
The Burden of Cardiovascular Disease in North Carolina Justus-Warren Heart Disease and Stroke Prevention Task Force April 11, 2018 Purpose 1. To detail the burden of heart disease and stroke in North Carolina
Annual High Claims Survey. Year Ending 31 December 2016
Annual High Claims Survey Year Ending 31 December 2016 Released July 2017 Summary The Private Healthcare Australia Annual High Claims Survey Report analyses the nature and magnitude of high claims met
Supplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification
Supplemental Digital Content: Definitions Based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Diagnose and Procedures Codes 1. ICD-9-CM definition of
10. Definition of cardiovascular disease 10.1 Nosologic definitions Acute myocardial infarction: myocardial cell death due to prolonged ischaemia 62.
10. Definition of cardiovascular disease 10.1 Nosologic definitions Acute myocardial infarction: myocardial cell death due to prolonged ischaemia 62. Acute coronary syndrome: it is a big category which
Covered Critical Illness Conditions Appendix
Covered Critical Illness Conditions Appendix Effective Date: February 1, 2010 This Appendix contains definitions for those Conditions that are covered under the Manulife Financial Group Critical Illness
Atrial fibrillation: a key determinant in the cardiovascular risk continuum. u Prof. Joseph S. Alpert u Arizona, USA
Atrial fibrillation: a key determinant in the cardiovascular risk continuum u Prof. Joseph S. Alpert u Arizona, USA Disclosures u No major conflicts of interest: all honoraria
Chronic Benefit Application Form Cardiovascular Disease and Diabetes
Chronic Benefit Application Form Cardiovascular Disease and Diabetes 19 West Street, Houghton, South Africa, 2198 Postnet Suite 411, Private Bag X1, Melrose Arch, 2076 Tel: +27 (11) 715 3000 Fax: +27 (11)
Lipids Testing
Previously Listed as Edit 12 190.23 - Lipids Testing Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol
Supplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
HAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest
HAS-BLED Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest r.pisters@mumc.nl Background major bleeding risk High stroke risk frequently warrants use of oral anticoagulation
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice
Atrial Fibrillation Ablation Recent Clinical Trials That Changed (or not) My Practice Walid Saliba, MD, FHRS Director, Atrial Fibrillation Center Director EP laboratory Heart and Vascular Institute Cleveland
CMS Limitations Guide - Cardiovascular Services
CMS Limitations Guide - Cardiovascular Services Starting October 1, 2015, CMS will update their existing medical necessity limitations on tests and procedures to correspond to ICD-10 codes. This limitations
Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban For preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (NICE TA 355) This document supports
PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS:
1 NAME: DATE OF BIRTH PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: PAST MEDICAL HISTORY (YOUR MEDICAL HISTORY) :
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually
Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code:
Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code: Date of Birth (MM/DD/YY): Social Security #: Sex: Male Female Home Phone #: Mobile Phone #: Email Address: Marital
Anti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
Manuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
HEART CONDITIONS IN SPORT
HEART CONDITIONS IN SPORT Dr. Anita Green CHD Risk Factors Smoking Hyperlipidaemia Hypertension Obesity Physical Inactivity Diabetes Risks are cumulative (multiplicative) Lifestyles predispose to RF One
Primary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
Chapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
V. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip
PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR ADVERSE EVENTS IN HIGH RISK ATRIAL FIBRILLATION PATIENTS TAKING ORAL ANTICOAGULATION THERAPY V. Roldán, F. Marín, B. Muiña, E. Jover,
How a universal health system reduces inequalities: lessons from England
How a universal health system reduces inequalities: lessons from England Appendix 1: Indicator Definitions Primary care supply Definition: Primary care supply is defined as the number of patients per full
Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
References: Murtagh J. Murtagh s General Practice. 5 th edn. Sydney: McGraw Hill; 2010.
This presentation is designed to be delivered to people who work in a health care setting; such as nurses, carers and other nursing home staff. If you are an accredited pharmacist, you can use this presentation
Results from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry
Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry E Van Belle, E Teiger, F Juthier, A Vincentelli, B Iung, H Eltchaninoff, J Fajadet,
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2017) in consultation
Using 3-Digit ICD-9-CM Codes with the Elixhauser Comorbidity Index
Congestive Heart Failure 398.91 Rheumatic heart failure (congestive) 398 Other rheumatic heart disease 402.01, 402.11, 402.91 402 Hypertensive heart disease 404.01, 404.03, 404.11, 404.13, 404.91, 404.93
Alma Mater Studiorum Università di Bologna
Alma Mater Studiorum Università di Bologna S.Orsola-Malpighi, Bologna, Italia Chirurgia Vascolare The volume of cerebral ischaemic lesion predicts the outcome after symptomatic carotid revascularisation
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
Many factors can increase the likelihood of platelets becoming spiky and hyperactive. These include:
Many factors can increase the likelihood of platelets becoming spiky and hyperactive. These include: Ageing Our body uses nitric oxide to calm platelets and keep blood vessels relaxed. However, the amount
ENROLLMENT : Line of Business Summary
ENROLLMENT : Line of Business Summary Date Range : JAN 2017 through DEC 2017 COMPREHENSIVE MAJOR MEDICAL Print Date : 1/19/2018 9:43:49AM Page 1 of 1 Month Year Single 2 Person : Emp/Spouse 2 Person :